Web8 apr. 2024 · NTLA Stock Overview Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. About the company Rewards Revenue is forecast to grow 48.92% per year Risk Analysis Currently unprofitable and not forecast to become profitable over the next 3 years Shareholders have been diluted in the past year WebMarch 21-23, 2024 Pechanga Resort Casino Southern California Registration is now open for the 2024 Tribal Land Staff National Conference! The 12th Tribal Land Staff National Conference will be held March 21-23, 2024 at the beautiful Pechanga Resort Casino in Southern California. Don't miss out on the many unique learning opportunities available …
Novel gene-editing therapy shows promise for patients with ...
Web6 apr. 2024 · Further, Intellia Therapeutics Inc. (NTLA) has a beta value of 1.87, and an average true range (ATR) of 2.11. Analysts have given the company’s stock an average 52-week price target of $94.69, forecast between a low of $39.00 and high of $168.00. Looking at the price targets, the low is -8.97% off current price level while to achieve the ... Web9 nov. 2024 · Intellia Therapeutics doses first patient in landmark CRISPR/Cas9 clinical trial of NTLA-2001 for the treatment of transthyretin amyloidosis. biology definition chromosome
NTLA-2002 in Adults With Hereditary Angioedema (HAE ...
Web16 feb. 2024 · As for NTLA-2002, the company plans to kick off the Phase 2 segment of the ongoing Phase 1/2 study during the first half of the year. An IND to get U.S. sites included in the Phase 2 study of NTLA-2002 should also be submitted during 1H. Despite a recent uptick, the stock has severely underperformed over the past year, having shed 54% of its … Web5 aug. 2024 · NTLA-2001 is an in vivo gene-editing therapeutic agent that is designed to treat ATTR amyloidosis by reducing the concentration of TTR in serum. It is based on the clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease (CRISPR-Cas9) system and comprises a lipid nanoparticle encapsulating … Web10 uur geleden · Another promising gene-editing therapy, NTLA-2001, is for transthyretin amyloidosis, a potential life-threatening illness that may impact the nerves, heart, kidney, … biology definition of biotic